Tweet
Although Roche/454 hasn't released Titanium amplicon sequencing yet, are there any 454 users here who have developed protocols/workarounds to sequence amplicons with Titanium chemistry?
-
-
In amplicon sequencing using 454 GS FLX, does sequencing ONLY start from the end with Linker B? Thank you. -
robhall -- You can sequence PCR products (amplicons) with the Titanium General Library method but employing their Low Molecular Weight (LMW) DNA variation. Basically you take your PCR product (70 - 800 bp), skip the fragmentation and size selection steps, polish the ends and then proceed with the standard library prep as normal. (There may be some minor variations or notes for LMW DNA so read the manual carefully before starting.) With this procedure vs. the standard amplicon procedure (using fusion primers) your PCR product is randomly oriented relative to the A and B adapters so you will get sequence reads from both ends of your PCR product.
para_seq -- The GS FLX Amplicon sequencing allows you to select either the A or B adapter to sequence from. There are two different emulsion PCR kits available which alternately orient the amplicon for sequencing; they are called emPCR Kit II (Primer A) and emPCR Kit III (Primer B). (emPCR Kit I is for shotgun libraries).Comment
-
kmcarr--
Thanks a lot.Comment
-
thanks kmcarr--we can give that a try. We are planning to multiplex and hoped to sequence from both directions at once, but I believe Roche/454 does have a tech bulletin for designing multiplex adapters with Titanium. We just wouldn't be able to control how equally we are sequencing in each orientation per amplicon.Comment
-
please also have a look at this thread:
flxlexComment
-
Hi kmcarr--Have you tried this? I'm curious if it has worked. My only worry is that the ligations won't work as well as they need to from PCR product ends, but I guess the end-polishing should take care of that?
-robhallComment
-
robhall -- No we have not done any LMW preps. But as you say, the end polishing should work as well on PCR products as fragmented DNA.Comment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment